Tau-targeting drugs gain fresh momentum in Alzheimer’s

Tau is normally a useful protein that supports the structural stability of neurons. In Alzheimer’s disease, it becomes chemically altered and starts to aggregate into what are called neurofibrillary tangles. These tangles accumulate inside neurons, disrupting their function and eventually causing cell death.

New clinical results, reported in Science, give cautious grounds for optimism about drugs that target this tau protein. The researchers describe how recent trial results have revived interest in tau as a treatment target, after years in which amyloid-targeting drugs dominated attention.

Two proteins, two approaches

The best-known current Alzheimer’s drugs, such as lecanemab, target amyloid. That approach has shown that removing amyloid can modestly slow the disease. But the effect is limited. The hypothesis is now that combining both approaches, targeting amyloid and tau together, might produce a greater benefit. Tau-directed therapies have therefore been tested in several large clinical trials.

What the new results show

The results show that some tau-targeting agents can measurably reduce protein aggregation in the brain. Whether this translates into fewer symptoms and slower cognitive decline has not yet been established definitively at this stage. The authors describe this as momentum for the field, not a breakthrough. Trials are ongoing, and larger studies must determine whether the clinical benefit is meaningful enough to help patients.

From a longevity perspective, this is notable: tau accumulation is not exclusive to Alzheimer’s. It also occurs in other forms of dementia and in normal brain aging, albeit to a lesser degree. Drugs that control tau could eventually have broader applications.

Read the original article